| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8740375 | Journal of Infection | 2018 | 21 Pages |
Abstract
As used in the participating centers, FQPx was associated with reduced Gram-negative BSI and improved survival among HDC patients. Among HSCT patients, the benefits were less clear. If adapted to local resistance patterns and patient characteristics, FQPx still may be useful in the management of patients with haematologic malignancies.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Winfried V. Kern, Susanne Weber, Markus Dettenkofer, Klaus Kaier, Hartmut Bertz, Michael Behnke, Maja Weisser, Tim Götting, Andreas F. Widmer, Christian Theilacker,